Journal article
CGRP receptor antagonists: A new frontier of anti-migraine medications
Drug discovery today. Therapeutic strategies, Vol.3(4), pp.593-597
2006
DOI: 10.1016/j.ddstr.2006.11.003
PMCID: PMC2751866
PMID: 19784396
Abstract
Migraine is a chronic pain condition that affects 12% of the population. Currently, the most effective treatments are the triptans, but they are limited in their efficacy and have potentially deleterious cardiovascular complications. On the basis of basic science studies over the past decade, a new generation of anti-migraine drugs is now being developed. At the forefront of these studies is a new calcitonin gene-related peptide (CGRP) receptor antagonist that is as effective as triptans in the acute treatment of migraines, without the cardiovascular effects. This review will address the likely mechanisms and therapeutic potential of CGRP receptor antagonists.
David Sibley – National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA
C. Anthony Altar – Psychiatric Genomics, Gaithersburg, USA
Theresa Branchek – Lundbeck Research, Paramus, USA
Details
- Title: Subtitle
- CGRP receptor antagonists: A new frontier of anti-migraine medications
- Creators
- Blanca Marquez de PradoAndrew F Russo
- Resource Type
- Journal article
- Publication Details
- Drug discovery today. Therapeutic strategies, Vol.3(4), pp.593-597
- DOI
- 10.1016/j.ddstr.2006.11.003
- PMID
- 19784396
- PMCID
- PMC2751866
- NLM abbreviation
- Drug Discov Today Ther Strateg
- ISSN
- 1740-6773
- eISSN
- 1740-6773
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 2006
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984019135902771
Metrics
20 Record Views